- Hematopoietic Stem Cell
- Skeletal Muscle Stem Cell
- Mesenchymal Stem Cells
Personalized Cell Therapies Market size was valued at USD 12,252.24 million in 2021, growing at a CAGR of 23.6% from 2022-28. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policymakers engaged in the manufacturing and supply of personalized cell therapies. Research & Development is evolving, various cell types developed into treatments as novel cell therapies due to its potential applications. Bone marrow transplant or hematopoietic stem cell transplant widely used cell therapy due to the treatment of blood cancer. Increased prevalence of cancer, a rise in research and adoption of advanced technologies are expected attract the demand for the market. Key Development: On August 19, 2016, the European Commission has granted conditional marketing authorization for Zalmoxis, patient-specific adjunctive treatment in haploidentical hematopoietic stem cell transplantation for adults with hematological malignancies.
Fastest Growing Market
The rise in prevalence of chronic disorders and unmet needs in current treatment methods are expected to catapult the personalized cell therapies market. Increasing prevalence of various disorders such as diabetes, cancer, autoimmune disorders, neurovascular disorders is expected to create demand for personalized cell therapies market over the forecast period. Moreover, potential applications of cell therapies include treating autoimmune disease, cancers, infectious disease, urinary problems, spinal cord injuries, rebuilding damaged cartilage in joints, improving a weakened immune system, neurological disorders are expected to create lucrative opportunities for the market.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.